Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07093580 · ClinicalTrials.gov registry record · Phase 1
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
A Phase 1 study of Healthy Participants, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT07093580 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Shionogi. The registered enrollment target is 98 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07093580, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG S-892216-LAI
Study Locations (2)
Kansas
- ICON Clinical Research: Lenexa - Lenexa
Utah
- ICON Clinical Research: Salt Lake City - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2027-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07093580
The ClinicalTrials.gov registry entry for NCT07093580 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% higher). The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07093580 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Utah.
Frequently Asked Questions
What is clinical trial NCT07093580 about?
NCT07093580 is a clinical study titled "Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants". The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
What is the current status of trial NCT07093580?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2025-07-29. Estimated completion is 2027-05-26.
What conditions does trial NCT07093580 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07093580?
The interventions under investigation include: Placebo (DRUG), S-892216-LAI (DRUG).
Who is sponsoring clinical trial NCT07093580?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07093580 being conducted?
This trial has 2 study locations across Kansas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.